BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

...tapered after discontinuations of miRNA candidates to treat HCV from Regulus Therapeutics Inc. (NASDAQ:RGLS) and Santaris Pharma A/S...
BioCentury | May 11, 2018
Finance

Amplifying oligos

...fell after two leading candidates to treat HCV from Ionis spinout Regulus Therapeutics Inc. and Santaris Pharma A/S...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

...and took a $30 million equity stake. And Roche , which acquired oligo therapeutics company Santaris Pharma A/S...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...the company partnered with Santaris Pharma A/S , which was since acquired by Roche , to use Santaris’...
BioCentury | Feb 10, 2016
Company News

Management tracks

...Diego, Calif.) named Michael Hodges CMO. He was CMO and head of drug development at Santaris Pharma A/S...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

...company has long-standing relationships in the area, such as with locked nucleic acid (LNA) company Santaris Pharma A/S...
BioCentury | Oct 4, 2014
Financial News

Forbion raises EUR 92M toward FCF III

...by Amgen Inc. (NASDAQ:AMGN) for $425 million up front in 2011, and nucleic acid specialist Santaris Pharma A/S...
BioCentury | Sep 8, 2014
Company News

Santaris, Roche deal

...Roche completed its acquisition of partner Santaris for $250 million in cash up front and up...
...million in cash up front and up to $200 million in undisclosed milestones. In January, Santaris...
...multiple undisclosed targets for several undisclosed disease areas (see BioCentury, Jan. 13 & Aug. 11). Santaris Pharma A/S...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

...For comparison, other 2014 acquisitions of venture-backed biotechs in Europe include Roche 's purchase of Santaris Pharma A/S...
...subsidiary of Kyowa Hakko Kirin Co. Ltd. for £230 million ($394.4 million) in cash. The Santaris...
...Brunswick, N.J. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Santaris Pharma A/S...
BioCentury | Aug 11, 2014
Finance

Leading with the LNA

...Given a choice between an acquisition and taking a chance on an IPO, investors in Santaris Pharma A/S...
...but the partners soon began takeout talks. Forbion's Martien van Osch, a Santaris director, said Santaris...
...said it and Santaris will review the biotech's portfolio and "make decisions in due time." Santaris'...
Items per page:
1 - 10 of 145
BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

...tapered after discontinuations of miRNA candidates to treat HCV from Regulus Therapeutics Inc. (NASDAQ:RGLS) and Santaris Pharma A/S...
BioCentury | May 11, 2018
Finance

Amplifying oligos

...fell after two leading candidates to treat HCV from Ionis spinout Regulus Therapeutics Inc. and Santaris Pharma A/S...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

...and took a $30 million equity stake. And Roche , which acquired oligo therapeutics company Santaris Pharma A/S...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...the company partnered with Santaris Pharma A/S , which was since acquired by Roche , to use Santaris’...
BioCentury | Feb 10, 2016
Company News

Management tracks

...Diego, Calif.) named Michael Hodges CMO. He was CMO and head of drug development at Santaris Pharma A/S...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

...company has long-standing relationships in the area, such as with locked nucleic acid (LNA) company Santaris Pharma A/S...
BioCentury | Oct 4, 2014
Financial News

Forbion raises EUR 92M toward FCF III

...by Amgen Inc. (NASDAQ:AMGN) for $425 million up front in 2011, and nucleic acid specialist Santaris Pharma A/S...
BioCentury | Sep 8, 2014
Company News

Santaris, Roche deal

...Roche completed its acquisition of partner Santaris for $250 million in cash up front and up...
...million in cash up front and up to $200 million in undisclosed milestones. In January, Santaris...
...multiple undisclosed targets for several undisclosed disease areas (see BioCentury, Jan. 13 & Aug. 11). Santaris Pharma A/S...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

...For comparison, other 2014 acquisitions of venture-backed biotechs in Europe include Roche 's purchase of Santaris Pharma A/S...
...subsidiary of Kyowa Hakko Kirin Co. Ltd. for £230 million ($394.4 million) in cash. The Santaris...
...Brunswick, N.J. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Santaris Pharma A/S...
BioCentury | Aug 11, 2014
Finance

Leading with the LNA

...Given a choice between an acquisition and taking a chance on an IPO, investors in Santaris Pharma A/S...
...but the partners soon began takeout talks. Forbion's Martien van Osch, a Santaris director, said Santaris...
...said it and Santaris will review the biotech's portfolio and "make decisions in due time." Santaris'...
Items per page:
1 - 10 of 145